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Abstract 
Objective: To assess whether immunodeficiency is associated with the most 
frequent non-AIDS-defining causes of death, in the era of combination 
antiretroviral therapy (cART). 
Design: Observational multicenter cohorts. 
Methods: 23 cohorts of adults with estimated dates of Human 
Immunodeficiency Virus (HIV) seroconversion. Patients were seroconverters 
followed within the cART era. Measurement were latest CD4; nadir CD4 and 
time spent with CD4 <350 cells/mm3. Outcomes were specific causes of 
death using a standardized classification. 
Results: Among 9,858 patients (71,230 person-years follow-up), 597 died, 
333 (55.7%) from non-AIDS-defining causes. Non-AIDS-defining infection, 
liver disease, non-AIDS-defining malignancy and cardiovascular disease 
(CVD) accounted for 53% of non-AIDS deaths. For each 100 cells/mm3 
increment in the latest CD4 count, we found a 64% (95%CI 58-69%) 
reduction in risk of death from AIDS-defining causes and significant 
reductions in death from non-AIDS infections (32, 18-44%), end-stage liver-
disease (33, 18-46%), and non-AIDS malignancies (34, 21-45%). These 
risks were also associated with nadir CD4 while cART-naïve and duration of 
exposure to immunosuppression. No relationship between risk of death from 
CVD and CD4 count was found although there was a raised risk associated 
with elevated HIV RNA.  
Conclusions: In the cART era, the most frequent non-AIDS-defining causes of 
death are associated with immunodeficiency, only CVD was associated with 
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high viral replication. Avoiding profound and mild immunodeficiency, through 
earlier initiation of cART, may impact on morbidity and mortality of HIV 
infected patients. 
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Introduction 
With the widespread use of combination antiretroviral therapy (cART), 
mortality from the Human Immunodeficiency Virus (HIV) infection has 
decreased from around 10-12 to 1-3 per 100 person-years [1-6]. As a 
consequence of increased survival, non-AIDS defining conditions, specifically 
malignancies, end stage liver disease, cardiovascular disease, severe 
infections and kidney disease [7-9], now account for between 50 to 66% of 
deaths that occur.  
 
There is growing evidence that the incidence of a variety of non-AIDS 
conditions may be associated with longer duration of immunodeficiency, even 
in cART treated patients [10-16]. Whether HIV infection itself explains these 
emerging causes of non-AIDS defining mortality through exposure to 
uncontrolled viral replication or to persistent immune suppression might have 
important implications in terms of the optimal timing of antiretroviral 
treatment. 
To date, most studies investigating cause-specific mortality in HIV infection 
have used data from prevalent cohorts and have restricted themselves to 
examining the current level of immunodeficiency, as measured by the latest 
CD4 cell count. However, the latest CD4 cell count may be a consequence of 
the event rather than its cause, if the event (or its treatment) has an 
immunodepressive effect, e.g cancer and chemotherapy. Other 
measurements of immunodeficiency, such as the nadir CD4 cell count or the 
time spent with a low CD4 cell count, may better reflect an individual’s prior 
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exposure to immunodeficiency, as they reveal, respectively, the most 
profound alteration to the immune system and the length of exposure to this 
condition. The impact of such markers may be more reliably assessed in the 
long-term follow-up of seroconverters, the vast majority of whom are 
followed prospectively shortly after seroconversion. In cohorts of such 
individuals, survival can be described from a similar date of origin for all 
patients and the measure of association between time-dependent markers 
and death will be less subject to bias [17]. 
We used data from CASCADE, a large multicenter collaboration of cohorts of 
HIV-infected individuals with well-estimated date of HIV seroconversion to 
investigate the relationships between non AIDS-defining deaths and HIV-
associated immunodeficiency in the era of cART. We also investigated 
whether this relationship was consistent when using different approaches to 
account for exposure to immunodeficiency. 
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Methods 
CASCADE (Concerted Action on SeroConversion to AIDS and Death in 
Europe) is a collaboration between the investigators of 23 cohorts in Europe, 
Canada and Australia who collect data on HIV-1 infected individuals for whom 
it is possible to reliably determine the date of HIV seroconversion [18]. The 
CASCADE database is updated annually and the current analysis is based on 
data merged in September 2006. 
 
Study population 
Patients older than 16 years at the time of seroconversion with available 
follow-up since 1st January 1996, the year in which cART became widely 
available, were eligible for inclusion in this current analysis. In addition, we 
selected individuals with at least two CD4 and HIV RNA measurements 
available more than six months after seroconversion. If treated with cART, 
patients were also required to have markers measured in the six months 
before and the 12 months after treatment initiation (regardless of CD4 count 
availability, all patients dying in the first year were retained in the analysis). 
 
Causes of death 
Classification of specific causes of death was based on the 1993 clinical 
definition of AIDS from the Centers for Disease Control [19], USA (i.e other 
clinical conditions were considered to be non AIDS-defining) and the 
International Classification of Diseases 10th Revision (ICD-10). Furthermore 
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the “Coding of Death in HIV” (CoDe) classification system was used to 
standardize causes of death reported by cohorts (www.cphiv.dk/CoDe). 
 
Statistical Methods 
Analyses were performed using the SAS® software v9 (SAS institute, Cary, 
NC). The cumulative incidence of each specific cause of death was estimated 
within a competing risk framework [20]. Person-years of follow-up (PYFU) 
were calculated from date of enrolment in the cohorts. The multivariate 
analysis used the cause-specific hazard in multivariable Cox proportional 
hazards models [21, 22], allowing the use of time-varying covariates. In Cox 
models, patients dying from causes other than those specifically studied were 
right-censored. Follow-up time was considered from the date of 
seroconversion to outcome or censoring date, with patients’ follow-up being 
right-censored on the last date known to be alive. The analyses allowed for 
late entry into the risk set in order to take into account the lag time between 
the estimated date of seroconversion and the latest of date of enrolment into 
the constituent CASCADE cohort, and dates of first CD4 count and HIV RNA 
assessment. Using this left truncation approach, we were able to adjust for 
possible bias in estimates due to the effect of survivorship. All analyses were 
stratified by cohort in order to take potential heterogeneity into account. 
We fitted separate multivariable models for the 10 most frequent causes of 
death and modelled the intensity and duration of immunodeficiency with the 
following time-dependent variables: (i) latest CD4 count; (ii) nadir CD4 cell 
count over the entire follow-up period to date; (iii) nadir CD4 cell count while 
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cART-naïve (nadir value over the entire follow-up period to date was used for 
those not yet starting cART); and (iv) cumulative time spent with a CD4 cell 
count <350 cells/mm3. Distinct models were developed for these four 
measures of immunodeficiency since they were highly correlated. 
Given that our cohort populations were frequently followed-up, CD4 count 
and HIV RNA values over follow-up (treated as time varying covariates) were 
each estimated using the moving average of the previous two reported 
measurements in order to minimize the impact of measurement error or 
erroneous data. The cumulative time spent at CD4 counts below 350 
cells/mm3 was assessed by allocating time on the basis of actual CD4 cell 
counts and was updated in the model each time a new CD4 count became 
available. 
Latest and nadir CD4 counts were categorized according to clinically relevant 
cut-offs, i.e <50, 50 to 199, 200 to 349 and ≥350 cells/mm3. Analyses were 
adjusted for other characteristics known to be associated with survival. Log10 
HIV RNA level, performed at the same time as the CD4 cell count, was 
categorised as <5 vs. ≥5 log10 copies/ml, as a marker of subsequent 
lymphocyte activation or endothelial activation to high HIV RNA replication. 
The choice of cut-off for time-dependent HIV RNA was based on the fact that 
HIV RNA distribution did not suggest a log-linear relationship, and the large 
number of patients who became undetectable during follow-up militated 
against its use as a continuous variable. We also adjusted for sex, age at 
seroconversion (which did not satisfy the assumption for log-linear risk 
association and was subsequently categorized as <35 vs. ≥35 years, to 
  
 
 11 
account for the increased risk of cancer and cardiovascular disease in older 
patients, as well as late entry into the risk set), exposure category (injecting 
drug use (IDU) vs. other modes), baseline hepatitis C (HCV) status. As 
treatments may also influence survival from some causes that are not AIDS-
defining [13, 23], we adjusted for initiation of cART as a time-dependent 
covariate. The analysis was performed on an intention-to-continue cART 
basis, ie. we ignored subsequent treatment changes. In a secondary analysis, 
we incorporated an interaction term between HIV RNA level and cART status 
(treated or not treated). Thus all analyses presented in this report are 
adjusted for CD4 cell count, HIV RNA level, age, sex, exposure category, HCV 
status and first line cART. 
In addition, we performed sensitivity analyses for cardiovascular and non-
AIDS defining malignancy deaths, using the CD4 count lagged by six months 
(i.e. the values incorporated into the model were all measured at least six 
months before death). This latter approach was taken to better disentangle 
the role of this marker as the cause, rather than the consequence, of the 
evolving condition leading to death. 
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Results 
Among 15,032 patients in CASCADE older than 16 years with available 
follow-up after 1st January 1996, 13,145 had CD4 cell count and HIV RNA 
measurements available at least once from six months after seroconversion 
(among whom 69% started cART during follow up). Of these, 2,484 treated 
patients did not have markers measured in the six-month period before or 
the twelve-month period after cART initiation, and a further 803 had fewer 
than two measurements of each marker. Among the 5,174 excluded patients 
(33,532 PYFU), 32% had seroconverted after 1996 and 689 deaths occurred 
(50% from AIDS-defining causes). Finally, 9,858 patients were included in 
our analysis. The patients were mostly male (77%) and had acquired HIV 
through sex between men (54%), between men and women (26%), or 
through injecting drug use (15%). Where Hepatitis C serostatus was known 
at seroconversion (79%), one fifth (21%) of patients were co-infected. The 
median date of HIV seroconversion was July 1996 and median age at 
seroconversion was 30 years (interquartile range: IQR, 25–36). The median 
time between the date of seroconversion and date of entry into the cohort 
was 6.6 months (IQR, 1.5–14.5). 
Per patient, a median of 12 measurements of HIV RNA (IQR, 5–23) and 15 
CD4 cell counts (IQR, 6–29) were available. For patients who died, the 
median lag times between the last available CD4 count or HIV RNA 
determination and death were 2.5 months (IQR, 1.0–5.6) and 3.0 months 
(IQR, 1.2–6.4), respectively.  
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Specific causes of death 
During 71,230 PYFU, 597 patients died. The 5-year and 10-year cumulative 
incidences for all-cause mortality were 1.5% and 5.7%, respectively. Most 
deaths were from non AIDS-defining causes (333 of 597), 178 (53%) of 
which were due to non-AIDS-defining infections (50 deaths), end-stage liver 
disease (46 deaths), non-AIDS-defining malignancies (46 deaths) or 
cardiovascular disease (36 deaths), (table 1). The 5-year cumulative 
incidence of these four specific causes of death were 0.15%, 0.03%, 0.06% 
and 0.05% and at 10 years it was 0.51%, 0.23%, 0.51% and 0.26%, 
respectively. 
 
Antiretroviral treatment 
Throughout follow-up, 6,530 patients (66.3%) started cART, 743 (7.5%) 
received only mono- or dual therapy while 2,585 (26.2%) remained 
untreated. Among the 6,530 patients who started cART, 3,884 (59.5%) were 
antiretroviral naïve when they started. The median time between 
seroconversion and cART initiation was 3.8 years (IQR, 1.3–7.3). Among 
those who started cART, the median CD4 cell count and HIV RNA level at 
treatment initiation were 324 cells/mm3 (IQR, 211–475) and 4.6 log10 
copies/ml (IQR, 3.7–5.2), respectively. Median CD4 cell count and HIV RNA 
levels measured, on average, 6 months ( 4 to 8 months) after cART initiation 
were 451 cells/mm3 [302-627] and 2.30 log10 copies/ml [1.69-2.95], 
respectively. At 12 months (8 to 16 months), they were 480 cells/mm3 [330-
670] and 2.30 log10 copies/ml [1.96-3.22]. 
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cART regimens were mostly PI-based (60%, including 9% with boosted PI-
based regimens) or non-nucleoside reverse transcriptase inhibitor-based 
(30%). Nucleoside reverse transcriptase inhibitor-based regimens alone 
accounted for 10% of initial regimens. 
Relationship between markers of immunodeficiency and specific 
causes of death 
For each 100 cell/mm3 increment in the latest CD4 count, there was a 32% 
reduction in the risk of all cause mortality (95% CI, 28-35%), after 
adjustment for the latest HIV RNA level, age, sex, exposure category, HCV 
serostatus and initiation of cART treatment (Figure 1). When examining 
specific causes of death, a two-thirds reduction in mortality per each 100 
cell/mm3 increment in CD4 lymphocytes was observed for AIDS-defining 
causes (64%, 58-69%). One-third reductions in risk were observed for non-
AIDS infections (32%, 18-44%), end-stage liver disease (33%, 18-46%), 
and non-AIDS malignancies (34%, 21-45%). Reduction in mortality from all 
other or unknown causes, with the exception of violent deaths (including 
suicide), was also associated with an increase in the latest CD4 count. The 
univariate relationship between the latest CD4 cell count and cardiovascular 
deaths (17% reduction, 2-29) was no longer significant after adjustment for 
latest HIV RNA level and the other covariates (14%, 95% CI= 27% decrease 
to 2% increase).  
There was a clear gradient effect between all markers of 
immunosuppression: the latest CD4 cell count, nadir CD4 cell count over the 
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entire follow up or while cART-naïve, and the cumulative time spent with CD4 
cells <350/mm3 and mortality from AIDS-defining causes, non AIDS-defining 
infections and respiratory diseases (Tables 2 and 3). There was a clear 
gradient effect of latest and nadir CD4 count (measured throughout follow-
up) on mortality from end-stage liver disease as well as substance abuse. A 
similar trend was apparent for deaths from non-AIDS malignancies, although 
no association was found between risk from these deaths and duration of 
time with a CD4 count <350 cells/mm3. Age at seroconversion was 
associated with a higher mortality from each specific cause of death. Patients 
older than 35 years at seroconversion had about twice the risk of dying from 
AIDS (HR=2.22 [95% CI, 1.50-3.28]), non AIDS infection (2.04 [95% CI, 
1.04-4.10]) and liver disease (2.28 [95% CI, 1.08-4.83]) than younger 
patients. The effect of age was even stronger for mortality due to non-AIDS 
cancer: 3.29 (95% CI, 1.76-6.15) and cardio-vascular diseases: 3.61 (95% 
CI, 1.69-7.72). There was no association between mortality due to 
cardiovascular causes and any of the markers of immunosuppression 
considered, although an association was apparent with the latest HIV RNA 
level. Mortality due to violence (including suicide) were not associated with 
any marker of immunodeficiency, or with the latest HIV RNA level.  
For the analysis of cardiovascular and non-AIDS defining malignancy deaths, 
we found hazard ratios within the same range when we considered the latest 
CD4 count measured at least six months before death (instead of the latest 
value available immediately preceding death). 
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Individuals with a high HIV RNA level, whether treated or not, had a 
significantly higher mortality from AIDS-defining and non-AIDS infectious 
causes (Table 4) even after adjusting for latest CD4 count. An association 
between liver disease mortality and a high HIV RNA level was only apparent 
among patients not on cART. Deaths from non-AIDS malignancies were not 
associated with HIV RNA level, whether the patient was receiving cART or 
not. Finally, deaths from cardiovascular causes were clearly associated with a 
higher HIV RNA level, regardless of cART (HR=3.86, 1.57-9.51). 
We did not correct type I error inflation for multiple comparisons, but most 
associations were highly significant (p<0.001) and would allow for more than 
50 comparisons, assuming an overall type I error of 0.05 in a conservative 
Bonferroni correction. 
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Discussion 
In this large collaboration of HIV seroconverter cohorts, non-AIDS defining 
causes contribute to more than half of deaths especially serious non-AIDS-
defining infections, malignancies, end-stage liver, cardiovascular and 
respiratory disease. We provide evidence for an association between these 
causes of death and several markers of immunodeficiency, with the exception 
of cardiovascular deaths which were, however, associated with higher levels 
of viral replication. 
Our analysis confirms that latest CD4 cell count is associated with a higher 
mortality from conditions not traditionally defined as opportunistic, i.e liver 
diseases, non AIDS-infections, respiratory diseases, as well as non AIDS-
malignancies, even when CD4 count measured at least six months before 
death was considered. In addition, we found a consistent and gradually 
increasing association between earlier markers of immunodeficiency, such as 
the nadir CD4 count, or duration of exposure to immunodeficiency, such as 
time spent with CD4 < 350/mm3 and these specific causes of non-AIDS 
defining deaths. Our analysis does not indicate a particular advantage of 
either CD4 cell marker compared to the latest CD4 cell count for non-AIDS 
related outcomes. However, the consistent finding of a raised risk of non-
AIDS defining death and cumulative time spent below CD4 < 350/mm3 
reveals important clinically-relevant information and provides a strong 
argument that HIV-infected patients may benefit from early initiation of 
antiretroviral treatment to reduce the risk of AIDS and non AIDS-related 
causes of death [24]. 
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In this study, high HIV RNA, but not CD4 cell markers, was associated with a 
higher risk of cardiovascular disease death. High HIV RNA level may be 
considered as a surrogate marker of HIV-related endothelial inflammatory 
activation, such as Interleukin -6 or ultra-sensitive C-reactive protein, that 
may be promoted through various mechanisms [25]. 
Our study shows in particular a specific association of immune depletion and 
mortality from liver and cancer which may be additionally related to the 
result of ageing [26], HCV and hepatitis B virus (HBV) infections, tobacco, 
alcohol, and injecting drug use [27-29] as well as to toxicities from 
antiretrovirals [30]. 
 
Our study also shows that liver disease is a frequent cause of death in the 
cART era, now that patients are surviving to experience this competing cause 
of death. Indeed, immunosuppression is associated with more rapid 
progression to liver fibrosis and cirrhosis [13, 31]. Mortality rates associated 
with end-stage liver disease may rise even further in the future due to the 
ageing of the HIV population, co-infections with viral hepatitis B and C, and 
long-term cART-related hepatotoxicities [32].  
A recent meta-analysis comparing the incidence of 28 types of cancer 
between HIV-infected patients, organ transplant recipients, and the general 
population, suggested that immunodeficiency was the main cause of cancer 
development [33]. Although HIV is usually not considered as an oncogenic 
virus, HIV infection may contribute to carcinogenesis by persistent 
inflammation mediated by cytokines especially as immunosuppression 
  
 
 19 
provides the immunologic background that favours the development of non-
AIDS-defining cancer [16, 34] and leads to a reduced ability to the control of 
oncogenic viruses [35]. 
 
Studies exploring the relationship between immunodeficiency and non-AIDS-
defining causes of death, however, have provided limited or biased evidence 
because they were based on small cohorts [36] or used models based on 
CD4 cell measurements immediately preceding death. This study confirms 
findings from prevalent cohorts reporting that the latest CD4 cell count and 
time since seroconversion were associated with deaths from both pre-AIDS 
[37, 38] and non-AIDS causes. In addition, results from the SMART trial 
clearly implicate immunodeficiency with the occurrence of several severe 
non-AIDS events, including major cardiovascular events, end-stage liver 
disease, malignancies and kidney complications [39, 40].  
 
Seroconverter cohorts, such as CASCADE, are better suited than prevalent 
HIV populations for studying the determinants of survival. As seroprevalent 
cohorts are recruited at various times after seroconversion with unknown HIV 
infection duration, early deaths might be missed leading to an 
underestimation of death rates and biased estimates of prognostic factors. In 
our analyses, the long duration of follow-up acquired for this population of 
seroconverters allowed us to assess four different approaches to model 
‘exposure’ to immunosuppression, which ensured that immunosuppression 
had preceded death, rather than simply reflected the effects of terminal 
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disease. Nevertheless, as all patients were under follow-up shortly after 
seroconversion, and based on inclusion criteria they may represent a selected 
population with earlier HIV diagnosis, closer follow-up, optimal HIV 
management and favourable outcome, as compared to a recent publication 
from the same collaboration [1]. In addition, patients started cART with a 
median CD4+ above 320/mm3, substantially higher than the level seen in 
many seroprevalent cohorts [41, 42], reflecting the fact that patients were 
managed in an optimal setting in the context of early HIV diagnosis. 
However, although the overall mortality and the cumulative incidence of 
specific causes of death might under-estimate that in the wider HIV-infected 
population [13, 15, 43-46], it is unlikely that the association between 
immunodeficiency and deaths from different causes would be greatly affected 
by this selection. Finally, the patients selected for this analysis might better 
reflect patients that are currently managed and followed-up by practitioners, 
as attested by a larger proportion of HIV acquisition in the more recent 
periods. 
The quality of our database depended on the accuracy of recording of cause 
of death in each cohort, with 82% of causes that could be classified. Deaths 
were standardized using the Coding of Causes of Death classification 
(www.cphiv.dk/CoDe) [11], which ensured homogeneous coding for the 
reason of death across cohorts. Nevertheless, we did not apply the central 
adjudication process as in controlled trials, due to the fact our categories of 
deaths were large and therefore misclassification unlikely. However, each 
cohort uses its own methods to collect source data and the process for 
  
 
 21 
selecting and validate an underlying cause of death may differ across 
cohorts, explaining that 18% of causes of death remained unknown. Anyway, 
in such a situation, the proportion of deaths attributed to AIDS have likely 
been overestimated as patients with different causes of death might have 
been more likely to be classified as AIDS-defining when their current CD4 cell 
count was low. As a result, this misclassification may lead to an under-
estimation of the relationship between non AIDS-defining causes of death 
and immunodeficiency. Thus, we do not believe that this bias could explain 
the strong associations with immunodeficiency that we observed.  
 
Treatment adherence was not available in the CASCADE dataset, however 
any clinically relevant effect would be captured by our primary exposure 
variables (HIV RNA and CD4 cell count). Besides, traditional risk factors for 
specific non-AIDS-defining causes of death, such as tobacco consumption, 
could not be included as they are currently not pooled in CASCADE. It is 
difficult, however, to see how many of these factors would confound any 
relationship with immunodeficiency.  
 
In conclusion, our results add to the growing body of evidence on the 
association of immunodepletion and important non-AIDS related morbidity 
[47] and mortality and underline the need for continued large scale 
collaborative HIV cohort collaborations. Our results also plead for the use of 
non-AIDS defining death and morbidities as endpoints in clinical trials 
evaluating antiretrovirals. As HIV-infected patients in industrialized countries 
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have higher life style related risks factors (e.g. alcohol and tobacco 
consumption) compared to the general population [29], programmes for 
aggressive management of life style related cardiovascular risk factors are 
paramount [48, 49]. The burden of infections points to the need for harm 
reduction programs especially for injecting drug users who are at higher risk 
of dying from non-AIDS-defining causes [50] in addition to improved 
management strategies for the treatment of chronic HCV and HBV infections.  
Most importantly, our data provide additional arguments for HIV screening 
programs of at-risk populations for the early detection and treatment of HIV 
infection.  
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Table 1. Markers of immunodeficiency according to specific causes of death, CASCADE collaboration, 1996-2006. 
Number % Median Median Median Median
  Patients thought to remain alive 9261 - 7.6 (3.4 - 11.9) 304 (204 - 432) 281 (180 - 413) 498 (351 - 682)
  Causes of death
     AIDS-defining death 158 26.5 8.6 (6.0 - 13.2) 42 (10 - 170) 24 (7 - 68)   45 (10 - 145)
     Non AIDS-defining infection 50 8.4 8.4 (5.2 - 14.5) 115 (39 - 240)  79 (28 - 188) 189 (32 - 397)
     Liver disease‡ 46 7.7 12.2 (9.8 - 15.2) 110 (53 - 215) 95 (39 - 200) 159 (96 - 308)
     Non AIDS-defining cancer 46 7.7 8.4 (7.0 - 12.6) 211 (97 - 308) 159 (76 - 254) 236 (134 - 406)
     Cardiovascular disease 36 6.0 11.0 (7.1 - 14.8) 170 (92 - 268) 149 (58 - 253) 270 (116 - 501)
     Suicide 38 6.4 7.7 (4.3 - 10.7) 298 (180 - 414) 291 (145 - 397) 513 (327 - 831)
     Substance abuse# 34 5.7 6.2 (4.6 - 9.7) 182 (81 - 403) 157 (46 - 388) 292 (100 - 483)
     Violent cause 20 3.3 7.5 (3.8 - 12.9) 337 (269 - 498) 318 (165 - 430) 629 (377 - 781)
     Respiratory disease 20 3.3 8.3 (6.6 - 10.6) 140 (15 - 258) 20 (5 - 171) 25 (5 - 356)
     Other medical cause 43 7.2 10.4 (7.0 - 12.3) 170 (88 - 306) 126 (42 - 239) 252 (88 - 455)
     Unknown cause 106 17.8 9.8 (5.8 - 13.0) 163 (80 - 274) 120 (47 - 252) 250 (103 - 430)
  Dead patients overall 597 100.0 9.0 (5.8 - 12.7) 150 (40 - 269) 100 (20 - 240) 190 (49 - 420)
* Time from sercoconversion is time from date of serconversion to date of death or censoring date (for those who remained alive)
IQR
Distribution
Time from 
seroconversion* (years)
CD4 count (/mm3)
Nadir prior to starting 
cART
Nadir over the entire 
follow-up
Latest marker†
IQR IQR IQR
† Latest marker is latest measurement of the CD4 count at the time of death or at last follow-up (for those who remained alive)
‡ Liver disease : death due to hepatitis B or C or end-stage liver failure
# Substance abuse : death due to injecting drugs, acute intoxication, alcohol
IQR : interquartile range
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Table 2. Adjusted cause-specific hazard ratios of progression to death associated with 
latest CD4 cell count (first column), nadir CD4 cell count over the entire follow up 
(second column) and nadir CD4 cell count while cART-naive (third column), CASCADE 
collaboration, 1996-2006. 
Adj HR* p-value Adj HR* p-value Adj HR* p-value
   CD4 count (/mm3)  < 0.0001  < 0.0001  < 0.0001
      349-200 vs ≥350 4.70 (2.46 - 8.99) 2.31 (1.06 - 5.02) 1.38 (0.73 - 2.64)
      199-50 vs ≥350 30.15 (16.79 - 54.15) 12.41 (6.13 - 25.14) 4.95 (2.74 - 8.94)
      <50 vs ≥350 157.58 (84.72 - 293.10) 67.92 (33.05 - 139.57) 15.66 (8.81 - 27.82)
   HIV RNA (log10/ml)  ≥5 2.21 (1.50 - 3.28)  < 0.0001 4.40 (3.03 - 6.41) < 0.0001 3.14 (2.17 - 4.55)  < 0.0001
   vs <5
   CD4 count (/mm3)  < 0.0001  < 0.0001 0.003
      349-200 vs ≥350 0.95 (0.36 - 2.48) 0.88 (0.30 - 2.55) 1.30 (0.53 - 3.22)
      199-50 vs ≥350 5.66 (2.49 - 12.86) 5.20 (2.09 - 12.92 3.98 (1.67 - 9.47)
      <50 vs ≥350 16.02 (5.91 - 43.45) 11.57 (3.99 - 33.47) 3.78 (1.39 - 10.26)
   HIV RNA (log10/ml)  ≥5 6.23 (3.14 - 12.38)  < 0.0001 9.24 (4.87 - 17.50)  < 0.0001 5.90 (3.18 - 10.97) < 0.0001
   vs <5
   CD4 count (/mm3)  < 0.0001 0.01 0.21
      349-200 vs ≥350 2.18 (0.88 - 5.36) 2.59 (0.80 - 8.39) 1.71 (0.67 - 4.38)
      199-50 vs ≥350 7.07 (3.02 - 16.54) 4.00 (1.22 - 13.09) 1.52 (0.56 - 4.15)
      <50 vs ≥350 6.57 (2.00 - 21.6) 7.99 (2.19 - 29.15) 2.96 (1.02 - 8.61)
   HIV RNA (log10/ml)  ≥5 1.31 (0.55 - 3.12) 0.54 1.85 (0.80 - 4.27) 0.15 2.48 (1.21 - 5.07) 0.012
   vs <5
   CD4 count (/mm3)  < 0.0001 0.015 0.02
      349-200 vs ≥350 2.74 (1.31 - 5.74) 1.87 (0.81 - 4.35) 2.24 (0.94 - 5.37)
      199-50 vs ≥350 5.42 (2.41 - 12.21) 1.92 (0.74 - 4.97) 1.92 (0.69 - 5.38)
      <50 vs ≥350 18.70 (5.91 - 60.46) 5.79 (1.94 - 17.22) 4.70 (1.75 - 12.61)
   HIV RNA (log10/ml)  ≥5 1.10 (0.39 - 3.14) 0.85 2.17 (0.82 - 5.72) 0.12 0.52 (0.16 - 1.74) 0.28
   vs <5
   CD4 count (/mm3) 0.14 0.66 0.38
      349-200 vs ≥350 1.15 (0.51 - 2.63) 1.43 (0.54 - 3.79) 1.69 (0.86 - 9.18)
      199-50 vs ≥350 0.89 (0.28 - 2.82) 1.21 (0.41 - 3.59) 1.55 (0.55 - 4.37)
      <50 vs ≥350 4.15 (1.14 - 15.17) 2.13 (0.57 - 7.99) 2.82 (0.64 - 4.43)
   HIV RNA (log10/ml)  ≥5 3.86 (1.57 - 9.51) 0.003 4.27 (1.84 - 9.93) 0.0007 1.68 (0.74 - 3.81) 0.22
   vs <5
   CD4 count (/mm3) 0.59 0.24 0.27
      349-200 vs ≥350 0.77 (0.38 - 1.58) 0.49 (0.25 - 0.99) 0.57 (0.29 - 1.13)
      199-50 vs ≥350 0.73 (0.33 - 1.61) 0.49 (0.20 - 1.22)
      <50 vs ≥350 1.01 (0.31 - 3.31) 0.85 (0.36 - 1.99)
   HIV RNA (log10/ml)  ≥5 0.34 (0.05 - 2.55) 0.29 0.31 (0.04 - 2.30) 0.25 0.91 (0.35 - 2.34) 0.84
   vs <5
   CD4 count (/mm3)  < 0,0001 0.004 0.08
      349-200 vs ≥350 1.06 (0.37 - 2.99) 0.89 (0.33 - 2.42) 0.69 (0.25 - 1.90)
      199-50 vs ≥350 6.09 (2.52 - 14.70) 2.35 (0.87 - 6.33) 2.50 (0.98 - 6.34)
      <50 vs ≥350 15.87 (4.59 - 54.96) 6.55 (2.02 - 21.24) 1.52 (0.48 - 4.79)
   HIV RNA (log10/ml)  ≥5 1.07 (0.34 - 3.35) 0.90 1.73 (0.57 - 5.23) 0.32 1.48 (0.57 - 3.83) 0.42
   vs <5
   CD4 count (/mm3) < 0.0001 < 0.0001 0.02
      349-200 vs ≥350 3.96 (1.11 - 14.17) 1.55 (0.32 - 7.52) 1.29 (0.32 - 5.23)
      199-50 vs ≥350 3.93 (0.70 - 22.14) 4.08 (0.85 - 19.71) 2.41 (0.55 - 10.53)
      <50 vs ≥350 80.79 (20.60 - 316.82) 28.15 (5.55 - 142.59) 7.62 (1.78 - 32.59)
   HIV RNA (log10/ml)  ≥5 3.19 (1.05 - 9.67) 0.04 6.60 (2.39 - 18.21) 0.0003 4.24 (1.52 - 11.87) 0.006
   vs <5
   CD4 count (/mm3) 0.0008 0.0003 0.005
      349-200 vs ≥350 1.89 (0.83 - 4.30) 2.63 (0.95 - 7.28) 1.45 (0.60 - 3.46)
      199-50 vs ≥350 4.28 (1.79 - 10.22) 6.79 (2.44 - 18.93) 4.11 (1.70 - 9.96)
      <50 vs ≥350 9.10 (2.67 - 31.02) 11.28 (3.23 - 39.40) 1.10 (0.32 - 3.82)
   HIV RNA (log10/ml)  ≥5 2.90 (1.22 - 6.93) 0.02 3.74 (1.65 - 8.46) 0.001 1.28 (0.49 - 3.38) 0.61
   vs <5
   CD4 count (/mm3) <0.0001 <0.0001 0.02
      349-200 vs ≥350 2.23 (1.33 - 3.73) 2.12 (1.13 - 3.98) 1.43 (0.81 - 2.53)
      199-50 vs ≥350 5.67 (3.33 - 9.65) 4.07 (2.12 - 7.82) 2.12 (1.14 - 3.91)
      <50 vs ≥350 14.48 (6.78 - 30.95) 8.65 (4.04 - 18.51) 2.63 (1.35 - 5.10)
   HIV RNA (log10/ml)  ≥5 1.02 (0.50 - 2.08) 0.95 1.63 (1.85 - 3.19) 0.15 1.37 (0.79 - 2.37) 0.26
   vs <5
† Latest CD4 count was categorized as 349-200 and <200 cells/mm3.
HR : Hazard ratio; 95% CI : 95% confidence interval.
95% CI
0.61 (0.20 - 1.87)
* Adjusted for HIV RNA level (latest value for models first and second column, and value prior to starting cART for third colunm) or CD4 (if HIV 
RNA) and age, sex, exposure category, Hepatitis C serostatus and first line cART.
95% CI95% CI
Latest CD4 Nadir CD4 over the entire follow-up Nadir while cART-naïve
Other cause
Unknown cause
AIDS death
non AIDS 
infection
Liver disease
non AIDS 
cancer
Cardiovascular 
disease
Violent cause†
Substance 
abuse
Respiratory 
disease
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Table 3. Adjusted cause-specific hazard ratios of progression to death associated with cumulative time spent below 350 cells/mm3, 
CASCADE collaboration, 1996-2006. 
Adj HR* p-value Adj HR* p-value Adj HR* p-value Adj HR* p-value Adj HR* p-value
Cumulative time spent 
bellow 350 cells/mm3
   0-1 year 1 <0.0001 1 0.007 1 0.02 1 0.17 1 0.56
   1-3 years 3.01 (1.76 - 5.13) 1.59 (0.63 - 4.04) 4.48 (1.65 - 12.16) 2.17 (1.00 - 4.72) 1.06 (0.38 - 2.99)
   3-6 years 6.24 (3.65 - 10.86) 4.55 (1.87 - 11.08) 2.13 (0.68 - 6.61) 1.69 (0.69 - 4.16) 1.09 (0.38 - 3.17)
   6 years and over 8.58 (4.61 - 15.96) 3.71 (1.26 - 10.95) 3.57 (1.20 - 10.60) 2.56 (0.93 - 7.07) 1.99 (0.70 - 5.64)
HIV RNA (log10/ml)  ≥5 8.29 (5.80 - 11.87) <0.0001 12.71 (6.55 - 22.59) <0.0001 2.28 (1.01 - 5.13) 0.047 2.48 (0.95 - 6.47) 0.06 4.69 (2.04 - 10.79) 0.0003
   vs <5
HR : Hazard ratio; 95% CI : 95% confidence interval.
* Adjusted for latest HIV RNA level or cumulative time bellow 350 CD4 cell count/mm3 (if HIV RNA) and age, sex, exposure category, Hepatitis C serostatus and first line cART.
Cardiovascular disease (n=36)
95% CI95% CI 95% CI
Liver disease death (n=46)  Non AIDS cancer (n=46)AIDS death (n=158) Non AIDS infection (n=50)
95% CI 95% CI
 
 
Table 4. Adjusted cause-specific hazard ratios of progression to death associated with HIV RNA level according to cART treatment, 
CASCADE collaboration, 1996-2006. 
Adj HR* p-value Adj HR* p-value Adj HR* p-value Adj HR* p-value Adj HR* p-value
   HIV RNA level in log10/ml
   <5 while not on cART 1 <0.0001 1 <0.0001 1 0.06 1 0.29 1 0.007
   <5 while on cART 0.43 (0.27 - 0.68) 0.35 (0.15 - 0.84) 1.02 (0.47 - 2.20) 0.89 (0.41 - 1.92) 1.34 (0.51 - 3.47)
   ≥5 while not on cART 3.18 (1.80 - 5.59) 7.13 (2.87 - 17.75) 4.14 (1.33 - 12.89) 1.95† (0.63 - 6.07) 5.81 (1.59 - 21.24)
   ≥5 while on cART 2.39 (1.36 - 4.18) 3.95 (1.49 - 10.48) 0.91 (0.22 - 3.86) 1.95
† (0.63 - 6.07) 4.70 (1.25 - 17.73)
* Adjusted for latest CD4 count, age, sex, exposure category, Hepatitis C serostatus
HR: Adjusted Hazard Ratio, 95% CI : 95% confidence interval
95% CI
AIDS death (n=158) Non AIDS infection (n=50)
95% CI 95% CI 95% CI 95% CI
† Following categories : latest HIV RNA level ≥ 5 log10 copies/ml while on cART or not were gathered for non AIDS cancer
Liver disease death (n=46)  Non AIDS cancer (n=46) Cardiovascular disease (n=36)
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Legend of figure: 
 
Figure 1. Adjusted cause-specific hazard ratios of progression to death associated with a 100 cell increment in the latest CD4 count, 
CASCADE collaboration, 1996-2006. 
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Figure 1 
 
 
Adjusted Hazard Ratio (per a 100 cell increment in the latest CD4 count)
Adjusted for latest HIV RNA level and age, sex, exposure category, Hepatitis C serostatus and first line cART.
Latest CD4 : median latest CD4 cells/mm3; Nadir CD4 : median nadir CD4 cells/mm3 prior to starting cART.  
All causes of death Latest CD4: 190   Nadir CD4: 150
AIDS defining death Latest CD4:   45   Nadir CD4:   42
Non AIDS infection Latest CD4: 180   Nadir CD4: 115
Liver disease death Latest CD4: 159   Nadir CD4: 110
Non AIDS cancer death Latest CD4: 236   Nadir CD4: 211
Cardiovascular disease death Latest CD4: 270   Nadir CD4: 170
0.68 (95% CI, 0.65-0.72)
0.36 (95% CI, 0.31-0.42)
0.68 (95% CI, 0.56-0.82) 
0.67 (95% CI, 0.54-0.82) 
0.66 (95% CI, 0.55-0.79) 
Violent cause of death Latest CD4: 536   Nadir CD4: 328
Substance abuse Latest CD4: 292   Nadir CD4: 182
Respiratory disease death Latest CD4:  25    Nadir CD4: 140
Other medical cause Latest CD4: 252   Nadir CD4: 170
Unknown cause Latest CD4: 250   Nadir CD4: 163
0.86 (95% CI, 0.73-1.02)
1.10 (95% CI, 1.00-1.20)
0.77 (95% CI, 0.64-0.94)
0.56 (95% CI, 0.41-0.76)
0.69 (95% CI, 0.58-0.83)
0.73 (95% CI, 0.65-0.82)
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Steering Committee: Julia Del Amo (Chair), Laurence Meyer (Vice Chair), Heiner C 
Bucher, Genevieve Chene, Deenan Pillay, Maria Prins, Magda Rosinska, Caroline Sabin, 
Giota Touloumi.  
 
Coordinating Centre: Kholoud Porter (Project Leader), Sara Lodi, A Sarah Walker, Abdel 
Babiker, Janet Darbyshire.  
 
Clinical Advisory Board: Heiner C Bucher, Andrea de Luca, Martin Fisher, Roberto Muga.  
 
Collaborators: Australia—Sydney AIDS Prospective Study and Sydney Primary HIV 
Infection cohort (John Kaldor, Tony Kelleher, Linda Gelgor, Tim Ramacciotti, David 
Cooper, Don Smith); Canada—South Alberta clinic (John Gill); Denmark—Copenhagen 
HIV Seroconverter Cohort (Louise Bruun Jørgensen, Claus Nielsen, Court Pedersen); 
Estonia—Tartu Ulikool (Irja Lutsar); France—Aquitaine cohort (Genevieve Chene, 
Francois Dabis, Rodolphe Thiebaut, Bernard Masquelier), French Hospital Database 
(Dominique Costagliola, Marguerite Guiguet), Lyon Primary Infection cohort (Philippe 
Vanhems), SEROCO cohort (Laurence Meyer, Faroudy Boufassa); Germany—German 
cohort (Osamah Hamouda, Claudia Kucherer); Greece— Greek Haemophilia cohort (Giota 
Touloumi, Nikos Pantazis, Angelos Hatzakis, Dimitrios Paraskevis, Anastasia 
Karafoulidou); Italy—Italian Seroconversion Study (Giovanni Rezza, Maria Dorrucci, 
Benedetta Longo, Claudia Balotta); Netherlands—Amsterdam Cohort Studies among 
homosexual men and drug users (Maria Prins, Liselotte van Asten, Akke van der Bij, 
Ronald Geskus, Roel Coutinho); Norway—Oslo and Ulleval Hospital cohorts (Mette 
Sannes, Oddbjorn Brubakk, Anne Eskild, Johan N Bruun); Poland— National Institute of 
Hygiene (Magdalena Rosinska); Portugal—Universidade Nova de Lisboa (Ricardo 
Camacho); Russia—Pasteur Institute (Tatyana Smolskaya); Spain—Badalona IDU 
hospital cohort (Roberto Muga), Barcelona IDU Cohort (Patricia Garcia de Olalla), Madrid 
cohort (Julia Del Amo, Jorge del Romero), Valencia IDU cohort (Santiago Perez-Hoyos, 
Ildefonso Hernandez Aguado); Switzerland—Swiss HIV cohort (Heiner C Bucher, Martin 
Rickenbach, Patrick Francioli); Ukraine—Perinatal Prevention of AIDS Initiative (Ruslan 
Malyuta); United Kingdom—Edinburgh Hospital cohort (Ray Brettle), Health Protection 
Agency (Valerie Delpech, Sam Lattimore, Gary Murphy, John Parry, Noel Gill), Royal Free 
haemophilia cohort (Caroline Sabin, Christine Lee), UK Register of HIV Seroconverters 
(Kholoud Porter, Anne Johnson, Andrew Phillips, Abdel Babiker, Janet Darbyshire, Valerie 
Delpech), University College London (Deenan Pillay), University of Oxford (Harold Jaffe). 
 
